Unknown

Dataset Information

0

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.


ABSTRACT: In CD34+ cells mobilization of patients with multiple myeloma (MM), the use of Cyclophosphamide (CTX) at a dose of 2 g/m2 has low efficacy although also lower toxicity. The suboptimal mobilizing effect of low-dose CTX, however, may be overcome by plerixafor (PLX) on demand. We conducted a prospective multicenter study in 138 patients with MM to evaluate CTX 2 g/m2 in association with granulocyte-colony stimulating factor (G-CSF) and on-demand PLX. We compared results with a historical group of MM patients (n = 138) mobilized using CTX at a dose of 4 g/m2. CD34+ cells greater than 2 × 106/kg in max three aphereses were harvested in 98.6% of patients in the on-demand PLX study group while in 84.0% in the historical group, (p = 0.0001). In the on-demand-PLX study group, a successful harvest greater than 5 × 106/kg in max three aphereses was observed in 85.5% of patients versus 62.3% of patients in the historical control group, (p=0.0001). In the on-demand-PLX study group, 4.3% (6/138) of patients had febrile complications. Salvage mobilization in the on-demand PLX study group was 1.4%. In conclusions, on-demand PLX + CTX 2 g/m2 + G-CSF 10 ?g/kg has higher efficacy and lower toxicity compared with CTX 4 g/m2 + G-CSF. An analysis of costs is presented.

SUBMITTER: Milone G 

PROVIDER: S-EPMC7649636 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.

Milone Giuseppe G   Conticello Concetta C   Leotta Salvatore S   Michieli Maria Grazia MG   Martino Massimo M   Marco Anna Lia Di ALD   Spadaro Andrea A   Cupri Alessandra A   Condorelli Annalisa A   Milone Giulio Antonio GA   Markovic Uros U   Sciortino Roberta R   Schininà Giovanni G   Moschetti Gaetano G   Villari Loredana L   Saccardi Riccardo R  

Leukemia research reports 20201030


In CD34+ cells mobilization of patients with multiple myeloma (MM), the use of Cyclophosphamide (CTX) at a dose of 2 g/m<sup>2</sup> has low efficacy although also lower toxicity. The suboptimal mobilizing effect of low-dose CTX, however, may be overcome by plerixafor (PLX) on demand. We conducted a prospective multicenter study in 138 patients with MM to evaluate CTX 2 g/m<sup>2</sup> in association with granulocyte-colony stimulating factor (G-CSF) and on-demand PLX. We compared results with a  ...[more]

Similar Datasets

| S-EPMC8378276 | biostudies-literature
| S-EPMC4512229 | biostudies-literature
| S-EPMC8338551 | biostudies-literature
| S-EPMC4777887 | biostudies-literature
| S-EPMC4490031 | biostudies-literature
| S-EPMC7817584 | biostudies-literature
| S-EPMC3065558 | biostudies-other
| S-EPMC6952568 | biostudies-literature
| S-EPMC3650087 | biostudies-literature
| S-EPMC3946357 | biostudies-literature